• Teva Page Title

Korporativne novice

Opomba: novice so v angleškem jeziku, povezave vodijo na korporativno stran podjetja Teva.

18.01.2017

Teva Receives FDA Approval for VANTRELATM ER (Hydrocodone Bitartrate) Extended-Release Tablets [CII] Formulated with Proprietary Abuse Deterrence Technology

VANTRELA ER label describes the product’s abuse-deterrent properties against abuse in the three most common routes—oral, intranasal and intravenous JERUSALEM--(BUSINESS WIRE)--Jan. 18, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) approved VANTRELATM ER (hydrocodone bitartrate) extended-release tablets [CII] formulated with Teva’s proprietary abuse deterrence technology. VANTRELA ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options...
09.01.2017

Teva Announces Completion of Sale of UK and Ireland Actavis Assets and Operations Following European Commission Approval

JERUSALEM--(BUSINESS WIRE)--Jan. 9, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the completion of the sale of the majority of the assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited (a subsidiary of Intas Pharmaceuticals Ltd). The sale, first announced in October last year, has completed for an agreed value of GBP 603 million following approval from the European Commission. The divestment of specified Actavis Generics assets and operations in the UK and Ireland was part of an undertaking that Teva made to the European Commission in order to obta...
06.01.2017

Teva to Present at the 35th Annual J.P. Morgan Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Jan. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the 35th Annual J.P. Morgan Healthcare Conference. Teva’s management will present on Monday, January 9, 2017 at 9:30 AM PST. What:   Teva Presentation at the 35th Annual J.P. Morgan Healthcare Conference   When: ...
06.01.2017

Teva Provides 2017 Financial Outlook

JERUSALEM--(BUSINESS WIRE)--Jan. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) provides its current outlook for non-GAAP financial performance for the year ending December 31, 2017. In an effort to enhance investor understanding of the Company’s business performance, and to provide more clarity and transparency regarding its projections for 2017, the following assumptions will apply to the 2017 non-GAAP financial outlook: Updated segmentation: Our generics segment will now include our OTC business; Our specialty seg...
05.01.2017

Teva to Host 2017 Business Outlook Conference Call and Webcast on January 6, 2017

JERUSALEM--(BUSINESS WIRE)--Jan. 5, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that it will host a conference call and live webcast on Friday, January 6, 2017 at 8:00 a.m. ET. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-966-1396; Canada 1-866-992-6802 or International +44(0) 2071 928000; passcode: 44010191. For a list of other international toll-free numbers, click here. A live webcast of the call will also be available on Teva's website at: www.ir.tevapharm.com. Please log in at least 10 minutes p...
22.12.2016

Teva Reaches Settlement with Government on FCPA

Settlement resolves previously disclosed past conduct and reflects Company’s robust compliance culture JERUSALEM--(BUSINESS WIRE)--Dec. 22, 2016-- Teva Pharmaceuticals Industries Ltd., (NYSE and TASE:TEVA) announced today the conclusion of negotiations with the United States government over violations of the Foreign Corrupt Practices Act (FCPA). Following Teva’s voluntary worldwide investigation into business practices, Teva and the U.S. Department of Justice (DOJ) and Securities and Exchange Commission (SEC) have agreed to a resolution to resolve previously disclosed investigations into conduct relating to three coun...
07.12.2016

Teva to Present at the Citi 2016 Global Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Dec. 7, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Citi 2016 Global Healthcare Conference. Erez Vigodman will present on Thursday, December 8, 2016 at 10:15 AM EST. What:             Teva Presentation at the Citi 2016 Global Healthcare Conference ...
06.12.2016

Teva Receives Positive Outcome for COPAXONE® Label in Europe

JERUSALEM--(BUSINESS WIRE)--Dec. 6, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that it has received a positive outcome through the variation procedure to remove the pregnancy contraindication from the European label for COPAXONE® (glatiramer acetate injection) 20 mg/mL. The product was originally authorized through a decentralized procedure in Europe. The removal of the pregnancy contraindication follows a Positive Variation Assessment Report issued by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA; Reference Member State), and agreed by all Conce...
05.12.2016

Teva Appoints Dipankar Bhattacharjee as President and Chief Executive Officer, Global Generic Medicines Group, Succeeding Siggi Olafsson

JERUSALEM--(BUSINESS WIRE)--Dec. 5, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Dipankar Bhattacharjee has been appointed President and Chief Executive Officer, Global Generic Medicines Group, effective today. Mr. Bhattacharjee, who has served as President and CEO of Teva Generics Europe since April 2013, succeeds Sigurdur (Siggi) Olafsson, who will step down from his role and remain active with the Company until officially retiring at the end of the first quarter of 2017 to ensure an orderly transition. Mr. Bhattacharjee will be based in the U.S. As President and CEO of Teva Gene...
30.11.2016

Teva to Present Oncology Data at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition

JERUSALEM--(BUSINESS WIRE)--Nov. 30, 2016-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that data on GRANIX® (tbo-filgrastim) Injection, TREANDA® (bendamustine HCl) Injection and TRISENOX® (arsenic trioxide) Injection will be presented during poster sessions at the 2016 ASH Annual Meeting to be held at the San Diego Convention Center in San Diego, CA on December 3-6, 2016. Additional bendamustine abstracts were also accepted for publication in an online issue of Blood to be issued during the annual meeting. “We look forward to sharing real world data and outcomes research from our Onco...